"Losartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
| Descriptor ID |
D019808
|
| MeSH Number(s) |
D02.455.426.559.389.185.475 D03.383.129.308.507 D03.383.129.617.467
|
| Concept/Terms |
Losartan- Losartan
- 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
Losartan Potassium- Losartan Potassium
- Potassium, Losartan
- Losartan Monopotassium Salt
- Monopotassium Salt, Losartan
- Salt, Losartan Monopotassium
|
Below are MeSH descriptors whose meaning is more general than "Losartan".
Below are MeSH descriptors whose meaning is more specific than "Losartan".
This graph shows the total number of publications written about "Losartan" by people in this website by year, and whether "Losartan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 4 | 1 | 5 |
| 2015 | 1 | 2 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 0 | 3 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Losartan" by people in Profiles.
-
Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints. J Cardiovasc Magn Reson. 2025; 27(1):101121.
-
Losartan May Not Prevent Vestibular Schwannoma Growth or Related Hearing Loss During Observation. Otol Neurotol. 2024 Jul 01; 45(6):690-695.
-
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A. 2023 05 09; 120(19):e2300706120.
-
Dysregulated myosin in Hermansky-Pudlak syndrome lung fibroblasts is associated with increased cell motility. Respir Res. 2022 Jun 23; 23(1):167.
-
Randomized placebo-controlled trial of losartan for pediatric NAFLD. Hepatology. 2022 08; 76(2):429-444.
-
A pilot clinical trial with losartan in Myhre syndrome. Am J Med Genet A. 2021 03; 185(3):702-709.
-
Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. J Pediatr. 2020 07; 222:213-220.e5.
-
Biologically Regulated Marrow Stimulation by Blocking TGF-?1 With Losartan Oral Administration Results in Hyaline-like Cartilage Repair: A Rabbit Osteochondral Defect Model. Am J Sports Med. 2020 03; 48(4):974-984.
-
Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis. Am J Respir Crit Care Med. 2020 02 01; 201(3):313-324.
-
Effect of Losartan and Fish Oil on Plasma IL-6 and Mobility in Older Persons. The ENRGISE Pilot Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. 2019 09 15; 74(10):1612-1619.